THE CHILDREN’S ONCOLOGY DRUG ALLIANCE is joining the research and resources of the University of New South Wales and its commercialization arm, NewSouth Innovations; The Kids’ Cancer Project, an Australia-based childhood cancer research charity; Novogen, an Australian oncology drug development company; and Nationwide Children’s Hospital in Columbus, Ohio, to help accelerate development of a therapeutic approach to neuroblastoma.
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.
